Every 8-K that Nautilus Biotechnolgy, Inc. (NAUT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NAUT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAUT filings page.
Nautilus Biotechnology, Inc. (NAUT) entered into a new Sales Agreement with TD Securities (USA), LLC on September 11, 2026 for an “at the market” offering program to sell up to $125,000,000 of common stock from time to time, with TD Cowen acting as sales agent and earning up to 3.0% of gross proceeds on shares sold. The company controls key sale parameters, may suspend or terminate the program, and is not obligated to sell any shares. The shares will be issued under a Form S-3 shelf registration statement filed the same day, after it is declared effective by the SEC. On the same date, Nautilus and TD Cowen mutually terminated their February 28, 2024 at-the-market Sales Agreement, under which no common stock had been sold.
Nautilus Biotechnology reported second quarter 2026 results, recognizing its first revenue of $0.2 million, primarily grant income from The Michael J. Fox Foundation and service revenue from its Iterative Mapping Early Access Program. Operating expenses were $15.9 million, down from $17.1 million a year earlier, resulting in a net loss of $14.5 million versus $15.0 million. Cash, cash equivalents and investments totaled $129.2 million as of June 30, 2026.
The company is reallocating resources to accelerate proteoform applications in response to strong customer interest. The Voyager platform is expected to open for pre-orders in early 2027, with instrument shipments beginning mid‑2027 alongside Tau and AKT1 proteoform assay kits and additional oncology proteoform assays through late 2027. Testing showed current assay configuration changes do not support a 2027 broadscale consumable kit at target specifications, and Nautilus plans to update the commercial timeline after further development.
Nautilus Biotechnology, Inc. reported the results of its 2026 annual stockholder meeting held on June 17, 2026. Of 127,078,855 common shares outstanding as of April 20, 2026, 85,002,191 were represented in person or by proxy, indicating strong participation.
Stockholders elected Class II directors Parag Mallick and Farzad Nazem, each to serve until the 2029 annual meeting. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.
In an advisory vote, stockholders approved the 2025 executive compensation program and expressed a preference to hold future advisory votes on executive pay every one year. The company plans to conduct annual Say on Pay votes until the next required frequency vote, scheduled no later than the 2032 annual meeting.
Nautilus Biotechnology reported first quarter 2026 results, showing lower spending and a narrower loss as it advances its proteomics platform toward commercialization. Operating expenses were $16.1 million, down 14% from $18.8 million a year earlier, mainly from lower salaries, stock-based compensation, and facilities costs.
Net loss improved to $14.7 million for the quarter, compared with $16.6 million in the prior-year period, or $0.12 per share versus $0.13. Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026, supporting ongoing development of the Voyager platform and the new Iterative Mapping Early Access Program.
During the quarter, Nautilus initiated its Iterative Mapping Early Access Program with Baylor College of Medicine, advanced Tau proteoform assay work with collaborators, and appointed a new Vice President of Global Sales to drive early customer expansion ahead of full commercial launch.
Nautilus Biotechnology reported lower operating expenses and a narrower net loss for the fourth quarter and full year 2025 as it advances its single‑molecule proteomics platform toward an expected commercial launch in late 2026. Operating expenses were $15.4 million in Q4 2025, down from $20.0 million a year earlier, and $66.8 million for 2025 versus $81.5 million in 2024, reflecting reduced salaries, stock-based compensation, development costs, and in‑process R&D.
Net loss improved to $13.8 million in Q4 2025 from $17.6 million in the prior-year quarter, and to $59.0 million for 2025 from $70.8 million in 2024. Cash, cash equivalents, and investments totaled $156.1 million as of December 31, 2025, and the company believes this will fund operations through 2027.
Nautilus highlighted progress in Tau proteoform work, a new broadscale assay format, a January 2026 Iterative Mapping Early Access Program, a Michael J. Fox Foundation-supported alpha‑synuclein collaboration, and unveiling of the Nautilus Voyager™ platform, while noting it does not anticipate material 2026 revenue and expects operating expenses to rise about 15–20% year over year.
Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance. The company received notice on November 3, 2025 that it meets Nasdaq Listing Rule 5550(a)(2) after its common stock closed at or above $1.00 per share for a minimum of ten consecutive business days. Nasdaq stated the matter is now closed.
Earlier in 2025, NAUT had fallen below the minimum bid-price requirement and was granted compliance periods through October 28, 2025, then transferred to The Nasdaq Capital Market on October 29, 2025 with additional time to cure. Regaining compliance supports the company’s continued listing on The Nasdaq Capital Market under the NAUT ticker.
Nautilus Biotechnology, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. The company reported these results through a press release dated October 28, 2025, which is included as Exhibit 99.1.
The report explains that this earnings information is being furnished, not filed, which affects how it is treated under securities laws and future regulatory filings. The filing itself does not detail the financial figures, directing readers instead to the accompanying press release.